No insider purchase over the last 90 days. The latest, by 국민연금공단, was filed 01 Jul 2026.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- ●Executives0DART
- 1,527,520 sharesKRXDART:20260701000184Canonical exit: 29 Sept 2026 (T+90)
- ●Executives0DART
- 46,427 sharesKRXDART:20260429000885
- 46,427 sharesShareKRXDART:20260429000881
- ●Executives0DART
- ●Executives0DART
- 16,312 sharesKRXDART:20260305001432
- 16,312 sharesShareKRXDART:20260305001431
- 8,783 sharesKRXDART:20260223003215
- 8,783 sharesShareKRXDART:20260223003297
- 303,911 sharesKRXDART:20260204000534
- 71,522 sharesShareKRXDART:20260204000533
- 232,389 sharesShareKRXDART:20260127000374
- ●Executives0DART
- ●Executives0DART
- 0KRXDART:20240926000319
- 0KRXDART:20240725000283
- 0KRXDART:20240531002428
- 788 sharesShareKRXDART:20240502000605Canonical exit: 24 Jul 2024 (T+90)
- 1,252 sharesShareKRXDART:20240502000593Canonical exit: 24 Jul 2024 (T+90)
25 of 42 declarations
About ISU Specialty Chemical Co., Ltd.
ISU Specialty Chemical Co., Ltd. (이수스페셜티케미컬) has one dominant filer: 이수, filed as 대량보유자, made 26 of the 38 filings, 3 purchases and 9 sales. 김성민 (부회장) has 5, with no purchase or sale, the company has 2, 김상범 has 2 purchases and 국민연금공단 has 1 purchase.
The record lists 8 purchases and 9 sales, 47% purchases, but no trade carries an amount, so no euro total can be worked out. 21 filings are of another kind. From April 2 to April 25, 2024, 4 filers bought.
Read moreShow less
Filings were published between May 31, 2023 and July 14, 2026, from 7 filers: 12 in 2023, 10 in 2024, only 2 in 2025, then 14 in 2026. Valued at KRW 2.6 trillion, this chemicals company shows a recent flow tilted to selling: the last 12 months hold 14 filings, 9 sales and 1 purchase. The median delay between trade and publication is 7 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
